CoChat

Fisetin for COVID ‐19 in skilled nursing facilities: Senolytic trials in the COVID era

Open access
Verdoorn, Brandon P., Evans, Tamara K., Hanson, Gregory J., Zhu, Yi, Langhi Prata, Larissa G. P., Pignolo, Robert J., Atkinson, Elizabeth J., Wissler‐Gerdes, Erin O., Kuchel, George A., Mannick, Joan B., Kritchevsky, Stephen B., Khosla, Sundeep, Rizza, Stacey A., Walston, Jeremy D., Musi, Nicolas, Lipsitz, Lewis A., Kiel, Douglas P., Yung, Raymond, LeBrasseur, Nathan K., Singh, Ravinder J., McCarthy, Teresa, Puskarich, Michael A., Niedernhofer, Laura J., Robbins, Paul D., Sorenson, Matthew, Tchkonia, Tamara, Kirkland, James L. · 2021 · Journal of the American Geriatrics Society
Cited by 50

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS‐CoV‐2 infection. SARS‐CoV‐2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence‐associated secretory phenotype (SASP). The SASP can be amplified by infection‐related pathogen‐associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS‐CoV‐2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS‐CoV‐2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health‐funded, multicenter, placebo‐controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS‐CoV‐2 rtPCR‐positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long‐term care settings in the SARS‐CoV‐2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jgs.17416

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 50

Metadata

Authors
Verdoorn, B. P., Evans, T. K., Hanson, G. J., Zhu, Y., Langhi Prata, L. G. P., Pignolo, R. J., Atkinson, E. J., Wissler‐Gerdes, E. O., Kuchel, G. A., Mannick, J. B., Kritchevsky, S. B., Khosla, S., Rizza, S. A., Walston, J. D., Musi, N., Lipsitz, L. A., Kiel, D. P., Yung, R., LeBrasseur, N. K., Singh, R. J., McCarthy, T., Puskarich, M. A., Niedernhofer, L. J., Robbins, P. D., Sorenson, M., Tchkonia, T., & Kirkland, J. L.
Venue
Journal of the American Geriatrics Society
Publisher
Wiley
Published
2021-08-20
Volume
69
Issue
11
Pages
3023-3033
ISSN
  • 0002-8614 (ISSN-L)
  • 1532-5415
OpenAlex
W3192450010
Cited by
50
References
8
FWCI
5.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fisetin for COVID ‐19 in skilled nursing facilities: Senolytic trials in the COVID era. https://app.cochat.ai/papers/10.1111/jgs.17416
The paper
Verdoorn, B. P., Evans, T. K., Hanson, G. J., Zhu, Y., Langhi Prata, L. G. P., Pignolo, R. J., Atkinson, E. J., Wissler‐Gerdes, E. O., Kuchel, G. A., Mannick, J. B., Kritchevsky, S. B., Khosla, S., Rizza, S. A., Walston, J. D., Musi, N., Lipsitz, L. A., Kiel, D. P., Yung, R., LeBrasseur, N. K., . . . Kirkland, J. L. (2021). Fisetin for COVID ‐19 in skilled nursing facilities: Senolytic trials in the COVID era. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.17416

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.